Table 1.

Clinical and laboratory characteristics of the study sample at time of enrollment considered as a whole and subdivided on the basis of the occurrence of non-fatal ischemic stroke or TIA events during the follow-up.

	All the subjects (n = 118)	No Stroke/TIA (n =94)	Stroke/TIA (n = 24)
Age (years)	68 (59–75)	68 (59–75)	68 (60–76)
Male gender (n, %)	79, 66.95	65, 69.15	14, 58.33
BMI (kg/m2)	26.45 (23.23–29.88)	26.63 (23.14–29.74)	25.89 (23.37–29.95)
Coronary artery disease (n, %)	62, 52.54	50, 53.19	12, 50.00
Previous stroke/TIA (n, %)	8, 6.78	6, 6.38	2, 8.33
Congestive heart failure (n, %)	10, 8.47	10, 10.63	0, 0.00
Atrial fibrillation (n, %)	62, 52.54	50, 53.19	12, 50.00
Diabetes (n, %)	25, 21.18	20, 21.28	5, 20.83
Hypertension (n, %)	66, 55.93	51,54.26	15, 62.50
Smoke habit (n,%)	50, 49.15	48, 51.06	10, 41.67
CHA 2 DS 2 -VASc score ( n , %)
0	18, 15.25	16, 17.02	2, 8.33
1	26, 22.03	21, 22.34	5, 20.83
≥2	74, 62.71	57, 60.64	17, 70.83
Laboratory parameters
Creatinine (μmol/L)	90.00 (77.70–105.03)	91.95 (79.28–105.10)	82.15 (75.72–94.21)
Total Cholesterol (mmol/L)	4.88 (4.02–5.89)	4.75 (3.98–5.72)	5.08 (4.37–5.97)
LDL Cholesterol (mmol/L)	3.15 (2.64–4.00)	3.17 (2.59–4.09)	3.12 (2.66–4.01)
HDL Cholesterol (mmol/L)	1.24 (1.04–1.46)	1.26 (1.05–1.49)	1.15 (1.01–1.38)
Triglyceride (mmol/L)	1.50 (1.10–1.98)	1.41 (1.09–1.98)	1.60 (1.13–2.03)
Apo AI (g/L)	1.32 (1.14–1.50)	1.33 (1.13–1.50)	1.27 (1.19–1.54)
Apo B (g/L)	0.95 (0.78–1.18)	0.94 (0.77–1.14)	1.09 (0.87–1.24)
Apo CIII (mg/dL)	10.30 (9.00–12.34)	9.89 (8.86–12.12)	11.51 (10.24–14.52)
Apo E (g/L)	0.036 (0.029–0.046)	0.037 (0.031–0.047)	0.034 (0.026–0.044)

Distributions of continuous variables were expressed as median value with interquartile range (IQR). Categorical variables were expressed as proportions.